SK3 Group (SKTO) Announces Licensing of Proprietary Cryo-Extraction Technique for Extracting Non-Psychoactive Cannabinoids
January 13 2014 - 11:39AM
Marketwired
SK3 Group (SKTO) Announces Licensing of Proprietary Cryo-Extraction
Technique for Extracting Non-Psychoactive Cannabinoids
LOS ANGELES, CA--(Marketwired - Jan 13, 2014) - SK3 Group,
Inc. (OTC Pink: SKTO) ("the Company") is pleased to announce that
Berkeley Bio-Organic Research Laboratories is seeking participants
to test their new proprietary cannabinoid-based skin care products
-- Dharmanol™ Topikoil™, and T-Hydrocan™ Topikoil™.
Numerous scientific studies, as well as a host of anecdotal
evidence, have shown that phyto-cannabinoids, and other elements of
cannabis / hemp, are active against various types of skin
disease. Research by Manuel Guzman at Complutense University
in Madrid, Spain has shown that cannabinoids decreased cancer cell
proliferation and spreading, decreased density of blood vessels
that provide nutrients to tumors, increased cancer cell death, and
inhibited tumor-cell metastatic spreading into nearby
organs. Much anecdotal evidence on the internet and elsewhere
has shown that cannabis oil, when placed on a wart, mole,
discoloration, or other growth, can cause numerous types of skin
imperfections to simply disappear in just a few weeks with daily
treatment.
Berkeley Bio will be testing two types of its proprietary
Topikoil™. T-Hydrocan™ Topikoil™ will be made with a substantial
dose of whole-plant cannabis extract containing fully activated
(decarboxylated) cannabinoids, as well as a wide array of terpenes,
terpenoids, and other steam-soluble elements of cannabis / hemp.
Dharmanol™ Topikoil™ contains non-psychoactive CBD (cannabidiol)
and a wide array of other non-psychoactive cannabinoids from
cannabis / hemp.
While the initial testing and rollout will focus on medical
cannabis patients in California, the Company intends to roll out
Dharmanol™ Topikoil™ nationwide based on the applicable regulations
of each state and the US Government.
Those wishing to participate will be provided with several
different topical preparations (lotions / salves) and will be
required to live in California and keep accurate records, including
taking before and after pictures. The testing will begin in
one to two months. To sign up, please email your contact
information to trials@medicalgreens.com.
"We are very pleased to be announcing these new products," said
Artemus Mayor, President of the Company. "Research has shown very
significant effectiveness of medical cannabis against a wide
variety of skin ailments, and the stories on the Internet of people
casually treating skin imperfections with cannabis topicals
abound. Not only is this product chemically different than
other similar products on the market, but our new products will
have consistent, measurable medical cannabis content that should
lead to more effective and targeted dosing. Adding this new
delivery system to our Dharmanol™ line of products will
substantially increase our market reach into new areas, directly
benefiting our bottom line. In addition, our experience with
these new products will assist in our development of an extended
release transdermal patch product as well as other products."
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
About SK3 SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SK3 Group, Inc. investors@medicalgreens.com Investor
Relations
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From May 2024 to Jun 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Jun 2023 to Jun 2024